Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Relvar contains a unique combination of long-lasting molecules* – fluticasone furoate and vilanterol.2 This means that once-daily dosing with Relvar provides continuous 24-hour efficacy with no drop in effectiveness towards the end of the 24-hour dosing interval.3–5
This graph has been independently created by GSK from the original data. The same results were first published in Bernstein DI, et al. J Asthma 2015;52:1073–1083.
Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets. Relvar is not indicated for the relief of acute bronchospasm.
While therapeutic effect is seen post-24 hours, the approved and recommended dosing for Relvar is once-daily.
This graph has been independently created by GSK from the original data. The same results were first published in Braithwaite I, et al. Respir Med 2016;19:115–121.
Randomised, double-blind, placebo-controlled, crossover study in 32 patients with mild-to-moderate asthma (FEV1 >60% predicted). Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets. Relvar is not indicated for the relief of acute bronchospasm.
While anti-inflammatory effect is seen post-24 hours, the approved and recommended dosing for Relvar is once-daily.
This graph has been independently created by GSK from the original data. The same results were first published in Bardsley G, et al. Respir Res 2018;19:133.
Randomised, double-blind, placebo-controlled, crossover study in 32 patients with mild-to-moderate asthma (FEV1 >60% predicted). Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets. Relvar is not indicated for the relief of acute bronchospasm.
Discover Relvar
Need help with this product?
Footnotes
*In vitro data: clinical relevance is uncertain.
Abbreviations
CI, confidence interval; FEV1, forced expiratory volume in one second; wm, weighted mean.
References
- GINA. Global strategy for asthma management and prevention, 2021. Available at: www.ginasthma.org. Accessed June 2023.
- Global Datasheet Fluticasone furoate/vilanterol: v11, March 2020.
- Bernstein DI, et al. J Asthma 2015;52:1073–1083.
- Braithwaite I, et al. Respir Med 2016;19:115–121.
- Bardsley G, et al. Respir Res 2018;19:133.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230008 June 2023
